



Cite this: *Biomater. Sci.*, 2015, 3, 112

Reducible, dibromomaleimide-linked polymers for gene delivery†

James-Kevin Y. Tan,* Jennifer L. Choi, Hua Wei, Joan G. Schellinger and Suzie H. Pun

Polycations have been successfully used as gene transfer vehicles both *in vitro* and *in vivo*; however, their cytotoxicity has been associated with increasing molecular weight. Polymers that can be rapidly degraded after internalization are typically better tolerated by mammalian cells compared to their non-degradable counterparts. Here, we report the use of a dibromomaleimide-alkyne (DBM-alkyne) linking agent to reversibly bridge cationic polymer segments for gene delivery and to provide site-specific functionalization by azide-alkyne cycloaddition chemistry. A panel of reducible and non-reducible, statistical copolymers of (2-dimethylamino)ethyl methacrylate (DMAEMA) and oligo(ethylene glycol)methyl ether methacrylate (OEGMA) were synthesized and evaluated. When complexed with plasmid DNA, the reducible and non-reducible polymers had comparable DNA condensation properties, sizes, and transfection efficiencies. When comparing cytotoxicity, the DBM-linked, reducible polymers were significantly less toxic than the non-reducible polymers. To demonstrate polymer functionalization by click chemistry, the DBM-linked polymers were tagged with an azide-fluorophore and were used to monitor cellular uptake. Overall, this polymer system introduces the use of a reversible linker, DBM-alkyne, to the area of gene delivery and allows for facile, orthogonal, and site-specific functionalization of gene delivery vehicles.

Received 10th July 2014,
Accepted 1st August 2014

DOI: 10.1039/c4bm00240g

www.rsc.org/biomaterialsscience

Introduction

Gene-based drugs typically require a carrier to facilitate delivery into cell nuclei, where they are transcribed and later translated into proteins that can elicit a therapeutic effect. While virally-derived carriers have been the preferred vectors in clinical trials, a number of safety concerns have arisen due to their ability to alter the genome (retrovirus and lentivirus) and activate the immune system.^{1–3} While non-viral vectors generally have lower transfection efficiencies compared to viral vectors, they offer potential safety advantages. A class of materials that is highly investigated for non-viral gene transfer is cationic polymers, which condense DNA through electrostatic interactions, protect cargo from early elimination, and can be readily functionalized with molecular targeting agents.^{4–7} One of the most effective and commonly used cationic polymers is polyethylenimine (PEI); however, it is non-degradable and has a high density of positive amino groups that contribute to its cytotoxicity.⁸ *In vivo*, PEI aggregates and accumulates in the lungs and liver upon systemic administration due to strong

electrostatic interactions with cell membranes, proteins, and the extracellular matrix.^{5,6} Several other cationic materials such as poly[L-lysine],^{9,10} chitosan,^{11–13} poly[(*N*-2-hydroxypropyl)methacrylamide] (pHPMA),^{14–16} and poly[(2-dimethylamino)ethyl methacrylate] (pDMAEMA)^{17–20} have also been investigated and are able to achieve transfection efficiencies comparable to that of PEI but with the advantage of improved cell viability. Nevertheless, cationic polymers such as pDMAEMA still have inherent cytotoxicity due to their non-degradable nature.^{20,21} To ameliorate these effects, degradable linkages have been incorporated into cationic polymers so they can dissociate into smaller, less toxic fragments.^{3,20,22,23} Two commonly used chemistries for synthesizing degradable polymers are reducible disulfide bonds and hydrolyzable ester bonds.^{20,21,24} Several degradable polymers containing ethylene imine units have been reported with comparable gene delivery efficiency to that of PEI but with reduced cytotoxicity.^{14,22,25,26}

Bromomaleimide-functional groups have recently been developed for their ability to reversibly react with thiols. For example, dibromomaleimide (DBM) has two bromines that can be substituted with free thiols to form two thioether bonds.²⁷ Upon the addition of an excess of thiols, the thioether bonds can be readily cleaved to regenerate the original, thiolated product. Since the cell cytoplasm contains reducing agents such as glutathione, intracellular bromomaleimide-linked conjugates can potentially be cleaved *in vivo*.

University of Washington, Department of Bioengineering and Molecular Engineering and Sciences Institute, William H. Foege Building, Box 355061, 3720 15th Ave NE, Seattle, WA 98195, USA. E-mail: spun@uw.edu; Fax: +1 206 543 3488; Tel: +1 206 685 3488

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c4bm00240g

In fact, these thioether bonds have been shown to be cleaved within 1 hour in the cytoplasm of mammalian cells.²⁸ Another advantage of DBM is that it has a third point of attachment off the maleimide group. This has allowed for a very site-specific and quantity-controlled conjugation of various moieties ranging from fluorophores to polymers.^{27–29}

Herein, we describe synthesis of cleavable gene delivery vehicles that utilize DBM as a reversible bridging agent for cationic polymer segments as well as a moiety for site-specific functionalization. A panel of reducible, statistical copolymers of DMAEMA and oligo(ethylene glycol)methyl ether methacrylate (OEGMA) were synthesized by reacting thiol-terminated polymers with a DBM-alkyne derivative. Polymer fragmentation in reducing environments was confirmed. While polymer reducibility did not significantly affect gene transfer ability, the reducible polymers were better tolerated by mammalian cells than their non-reducible analogs. We further demonstrated site-specific modification of polymers by click conjugation of an azide-functionalized fluorophore to the alkyne site. Fluorophore-labeled polymers were used to monitor polyplex uptake by flow cytometry. Overall, the DBM-alkyne derivative offers a facile way to reversibly connect different polymers for gene delivery while the alkyne allows for the site-specific functionalization of polymers.

Materials and methods

Materials

Reagents for solid phase peptide synthesis were purchased from Apptec (Louisville, KY) except 5-azido pentanoic acid which was purchased from Bachem (Torrance, CA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture reagents were purchased from Cellgro/Mediatech (Fisher Scientific, Pittsburgh PA). The pCMV-Luc2 plasmid was isolated using the Qiagen Plasmid Giga Kit (Hilden, Germany). The bicinchoninic acid (BCA) protein quantification assay kit was purchased from Thermo Fischer Scientific (Waltham, MA) while the luciferase expression quantification kit and MTS assay kit were obtained from Promega (Madison, WI).

Polymer synthesis and characterization

Synthesis of dibromomaleimide-alkyne. Dibromomaleic anhydride was synthesized as previously reported (ESI†).³⁰ Propargylamine (0.1 mL, 1.6 mmol), dibromomaleic anhydride (0.6 g, 2.2 mmol), and 34 mL of glacial acetic acid were added to a reaction vessel and refluxed at 120 °C for 5 hours with stirring. Afterwards, the reaction vessel was cooled to room temperature and the glacial acetic acid was azeotropically removed with toluene under reduced pressure. The crude DBM-alkyne was dissolved in DCM and isolated by silica gel column (10:0.5 hexane–ethyl acetate) to yield the product as an off-white powder (0.38 g, 82%). The product identity and purity was confirmed by GC-MS on a Hewlett-Packard (Palo Alto, CA) 5971A GC-MSD.

ATRP copolymerization of DMAEMA and OEGMA. A double-headed atom-transfer radical polymerization (ATRP) initiator with an internal disulfide bond was prepared by *N,N'*-dicyclohexylcarbodiimide coupling between 2-hydroxyethyl disulfide and 2-bromo-2-methylpropionic acid (ESI†). Reducible p(DMAEMA-*s*-OEGMA) containing an internal disulfide bond was synthesized by ATRP using the double-headed ATRP initiator and CuCl/bpy as the catalyst. Polymers of three different sizes were synthesized by changing the monomer ratio; these polymers were called low molecular weight (MW) (~15k), medium MW (~20k), and high MW (~40k). Briefly, double-headed ATRP initiator (0.27 g, 0.06 mmol), DMAEMA (1.5 mmol, 3.0 mmol, or 6 mmol), OEGMA (0.3 mmol, 0.6 mmol, or 1.2 mmol), and bpy (37.48 mg, 0.24 mmol) were dissolved in isopropanol to a final monomer concentration of 2 M. The solution was sparged for 15 min with Ar. CuCl (11.88 mg, 0.12 mmol) was added and the solution continued to sparge for 3 minutes before immersing the flask in an oil bath preheated to 40 °C. After 6 hours, the flask was taken out and vented to quench the reaction. The solution underwent exhaustive dialysis for 3 days to remove the copper catalyst and subsequently lyophilized to yield a slightly opaque solid gel. Non-reducible p(DMAEMA-*s*-OEGMA) analogs were similarly synthesized with an ethyl α -bromoisobutyrate initiator (8.80 μ L, 0.06 mmol), DMAEMA (3 mmol, 6.0 mmol, or 12.0 mmol), OEGMA (0.6 mmol, 1.2 mmol, or 2.4 mmol), bpy (18.74 mg, 0.12 mmol), and CuCl (5.94 mg, 0.06 mmol). ¹H NMR in CDCl₃ was used to determine the ratio of DMAEMA to OEGMA by comparing the ester methylene peaks of DMAEMA and OEGMA (3.9–4.2 ppm) to the methoxy peak of OEGMA (3.3–3.4 ppm). To determine molecular weight and polydispersity (PDI), aqueous SEC-MALLS was performed in 1:1 methanol–300 mM acetate buffer pH 4.4 on a Shodex (Kawasaki, Japan) SB-804 HQ column connected to a Shimadzu (Kyoto, Japan) LC-20AD liquid chromatography pump and Wyatt (Sana Barbara, CA) MiniDawn Treos and Optilab rEX system. Number and weight average molecular weight (M_n and M_w) and dn/dc values were calculated using ASTRA software (Wyatt).

p(DMAEMA-*s*-OEGMA) substitution to DBM-alkyne. Reducible p(DMAEMA-*s*-OEGMA) (5.0 μ mol) and tris(2-carboxyethyl)-phosphine (TCEP) (0.7 mg, 5.5 μ mol) were dissolved in 3:1 (v/v) DMF–0.05 mM PBS to a final concentration of 0.02 M. The solution was stirred for 30 minutes before the addition of DBM-alkyne (1.5 mg, 5.0 μ mol). After 2 hours of stirring, the solution was dialyzed to remove DMF and salts and subsequently lyophilized to yield an orange solid gel. Polymers were characterized by aqueous SEC as mentioned previously.

Glutathione reduction assay. DBM-substituted and non-reducible p(DMAEMA-*s*-OEGMA) were dissolved in a cytoplasmic mimic buffer (20 mM HEPES, 100 mM KCl, 1 mM MgCl₂, 1 mM EDTA, and 1 mM glutathione, pH 7.4) to a final concentration of 0.1 mM. After 2 hours of stirring, aqueous SEC-MALLS was performed as mentioned previously.

Fluorophore cycloaddition to DBM-alkyne. DBM-substituted polymer (0.34 μ mol), *N,N,N',N',N''*-pentamethyldiethylenetriamine

(0.34 μmol), and azide-tetramethylrhodamine (0.34 μmol) were dissolved in 2 mL of DMF. The solution was sparged with Ar for 3 minutes, Cu(I)Br (0.34 μmol) was added, and then sparged for an additional 2 minutes. The vessel was placed in an oil bath at 60 °C for 24 hours. Afterwards, the solution was precipitated twice into ether, dialyzed, and lyophilized.

Polyplex characterization

Polyplex formation. The pCMV-Luc2 plasmid was diluted in double distilled H₂O (ddH₂O) to a concentration of 0.1 mg mL⁻¹ and mixed with an equal volume of polymer (in ddH₂O) at the desired amine to phosphate (N/P) ratio. The required amount of polymer was calculated by determining the polymer mass to charge ratio and taking into account that 1 μg of DNA contains 3 nmol of phosphate. After mixing, the polyplexes were allowed to form for 10 min at room temperature.

DNA complexation by agarose gel retardation. The ability of the cationic polymers to bind with DNA was assessed by a gel retardation assay. The polyplexes (1 μg DNA, 20 μL solution, various N/P ratios) with 10% (v/v) BlueJuice™ gel loading buffer (Invitrogen, Carlsbad, CA) were loaded onto a 1% agarose gel containing TAE buffer (40 mM tris-acetate, 1 mM EDTA) and 5 mg mL⁻¹ ethidium bromide. The gel was electrophoresed at 100 V for 40 min. The plasmid DNA was then visualized using a Kodak (Rochester, NY) UV transilluminator (laser-excited fluorescence gel scanner).

Polyplex sizing and surface charge analysis. Polyplexes were formed at the same concentration as previously stated but at half the volume. Briefly, polyplexes (0.5 μg DNA, 10 μL solution, N/P = 5 and 10) were mixed with either 90 μL of ddH₂O or PBS. A Brookhaven Instruments Corporation (Holtville, NY) ZetaPLUS instrument was used to determine the particle size by dynamic light scattering (DLS) and surface charge by zeta potential measurements.

Polyplex unpackaging. The pCMV-Luc2 plasmid was mixed with the bis-intercalating dye YOYO-1 iodide (Invitrogen, Carlsbad, CA) at a dye to base pair ratio of 1 : 100 and incubated at room temperature for 1 hour.

Polyplexes were prepared at an N/P = 10 by complexing YOYO-labeled plasmid with reducible and non-reducible polymers as previously mentioned. Polyplexes were pre-treated with 1 mM glutathione for 8 hours and then treated with 5 μg mL⁻¹ heparin sulfate for 1 hour. The fluorescence (ex: 491 nm, ex: 509 nm) of each well was normalized to its respective DNA only control.

In vitro studies

Luciferase plasmid transfection. Human epithelial adenocarcinoma cells (HeLa) were seeded in 10% FBS and 1% AbAm antibiotic supplemented MEM culture medium into a 24-well plate at a density of 3.0×10^4 cells per well. Cells were placed in a 37 °C, 5% CO₂, humidified incubator for 16 hours prior to transfection (60% confluency at time of polymer addition). Polyplexes were formed as previously described at N/P = 5 and 10 using 1 μg of pCMV-Luc2 plasmid DNA in 20 μL of total volume. Polyplexes were incubated with cells in OptiMEM™ or

complete media for 4 hours; afterwards, polyplexes were washed off and replaced with fresh complete media. After an additional 44 hours, cells were lysed and analyzed by a luciferase quantification expression kit and BCA assay for total protein content. Protein content was used to normalize luciferase expression as well as quantify cell population viability.

IC₅₀ study. HeLa cells were seeded at 5.0×10^3 cells per well in a 96-well plate as mentioned above. Non-reducible and reducible, DBM-substituted polymers at various concentrations were incubated with the cells in serum for 4 hours and were subsequently replaced with fresh serum media. After an additional 44 hours, an MTS assay was conducted to assess cell viability. Half maximal inhibitory concentration (IC₅₀) was calculated with Graphpad (La Jolla, CA) using a non-linear regression fit with variable slope.

Flow cytometry uptake study. HeLa cells were plated as described above at a density of 7.5×10^4 cells per well. Polyplexes of non-functionalized and fluorophore-functionalized polymer were formed with DNA at N/P ratios = 5 and 10 in OptiMEM™ as described above. Fluorophore only, polymer polyplexes, polymer polyplexes with free fluorophore, and fluorophore-polymer polyplexes were incubated with cells for 1 hour. Cells were then washed with PBS and CellScrub™ before analysis with a MACSQuant (Miltenyi, Bergisch Gladbach, Germany) flow cytometer. Analysis was performed with FlowJo analysis software (Tree Star, Ashland, Oregon).

Statistical analysis

All statistical analyses were performed using a two-tailed Student's *t*-test with unequal variance.

Results and discussion

Polymer synthesis and characterization

Three cationic, reducible polymers were synthesized by substituting a DBM-alkyne molecule with thiolated copolymers of DMAEMA and OEGMA (Scheme 1a). DBM-alkyne was synthesized as previously reported (Fig. S1 & S2†).²⁷ A double-headed ATRP initiator with an internal disulfide was prepared by *N,N'*-dicyclohexylcarbodiimide coupling between 2-hydroxyethyl disulfide and 2-bromo-2-methylpropionic acid (Fig. S3†). The double-headed initiator was used to prepare statistical copolymers of DMAEMA and OEGMA with low (~10 kDa), medium (~20 kDa), and high (~40 kDa) target molecular weights (Table 1). The DMAEMA monomer provides cationic charge for DNA condensation while the OEGMA affords colloidal stability as reported previously for similar systems.^{20,21,31} The resulting p(DMAEMA-*s*-OEGMA) materials possessed near-target molecular weights and compositions close to monomer feed ratios (5:1 DMAEMA to OEGMA) (Fig. S4†). These parent p(DMAEMA-*s*-OEGMA) polymers were reduced with TCEP to generate thiol-terminated fragments that were substituted onto DBM-alkyne. Under SEC-MALLS analysis, TCEP reduction caused a delayed elution compared to the elution of the parent polymers due to the reduction of



Scheme 1 (a) Synthesis of fluorophore-functionalized, DBM-substituted p(DMAEMA-s-OEGMA); (b) Synthesis of non-reducible p(DMAEMA-s-OEGMA).

the disulfide bond and decreased molecular weight (Fig. 1). DBM-alkyne was added to the thiolated polymers in the presence of TCEP to prevent disulfide formation and to yield the DBM-substituted polymers. The SEC traces of the DBM-substituted polymers were shifted to the earlier elution times, as expected for the increased molecular weight due to polymer

Table 1 Characterization of various DMAEMA and OEGMA statistical copolymers

Type of polymer		Determined M_n (kDa) ^a	M_w/M_n ^a	Determined DMAEMA : OEGMA ratio ^b
Parent p(DMAEMA-s-OEGMA)	Low	13 080	1.31	5.11
	Medium	21 010	1.42	5.41
	High	40 090	1.55	6.23
DBM-substituted p(DMAEMA-s-OEGMA)	Low	15 440	1.24	5.11
	Medium	23 810	1.38	5.41
	High	35 770	1.49	6.23
Non-reducible p(DMAEMA-s-OEGMA)	Low	10 170	1.29	4.61
	Medium	19 490	1.31	4.91
	High	42 220	1.85	4.17

^a Determined by SEC-MALLS. ^b Determined by ¹H NMR.

substitution (Fig. 1 and Table 1). The reaction was rapid and highly efficient as only equimolar amounts of parent polymer and DBM-alkyne were needed. Excess TCEP ensured the complete reduction of parent p(DMAEMA-s-OEGMA) and did not reduce the newly formed thioether bonds. Furthermore, the substituted polymers showed a new increase in UV absorbance and exhibited fluorescent properties [data not shown]. These findings are consistent with reports of other substituted dibromo-maleimides.^{27,29,30,32} As non-reducible controls, polymers of similar molecular weights were polymerized with a conventional ATRP initiator, α -bromoisobutyrate (Scheme 1b). The non-reducible polymers had molecular weights similar to those of the substituted polymers and monomer incorporations close to the initial feed ratio (5 : 1 DMAEMA to OEGMA) (Table 1 and Fig. S4[†]).

Larger molecular weight pDMAEMA has been correlated with higher cytotoxicity.³³ Unlike the slow hydrolysis rate of DMAEMA esters,²¹ the DBM-substituted polymers should be more rapidly reduced after intracellular uptake of the polyplexes in order to facilitate cargo release and reduce cytotoxicity. To demonstrate polymer reduction under physiological conditions, DBM-substituted polymers were incubated in a cytoplasmic mimic buffer²⁷ containing 1 mM glutathione reducing agent for 2 hours and analyzed by SEC (Fig. 2a). Substituted polymers with glutathione had a delayed elution compared to the peak of the DBM-substituted polymers, demonstrating that the thioether bonds in the copolymer were cleaved by glutathione. The reducibility of this polymer system is consistent with other DBM systems and suggests that the material can be cleaved in the reducing environment of the cell cytoplasm.^{27,28,34} Non-reducible polymers were also incubated with glutathione and analyzed by SEC (Fig. 2b). No peak shift was seen in the SEC traces for the non-reducible polymers.

Characterization of polyplexes

Polyplexes were formed by mixing the polymers with plasmid DNA at various amine to phosphate (N/P) ratios. The ability of the polyplexes to complex DNA was assessed by a gel retardation assay (Fig. S5[†]). Complete complexation of DNA




Fig. 1 SEC traces of (a) low, (b) medium, and (c) high molecular weight parent, reduced, and DBM-substituted DMAEMA and OEGMA copolymers. Parent polymers were reduced with TCEP (right-shifted trace) and resulting thiolated polymer fragments were substituted to DBM-alkyne (overlapping trace with parent polymer).




Fig. 2 SEC traces of (a) DBM-substituted and (b) non-reducible DMAEMA and OEGMA copolymers with glutathione. The copolymers were incubated in a cell cytoplasm mimic buffer containing 20 mM HEPES, 100 mM KCl, 1 mM MgCl₂, 1 mM EDTA, and 1 mM glutathione, pH 7.4. Incubation with glutathione reduced the DBM-substituted polymers and caused a rightward peak shift, signifying a decrease in MW.

was observed starting at an N/P = 2 for reducible and non-reducible copolymers, suggesting that DBM-alkyne and the reducible thioethers did not affect DNA condensation. Polyplexes formed at N/P = 5 and 10 were characterized by DLS in either ddH₂O or PBS containing physiological salt concentrations (Fig. 3). In water, reducible polyplexes showed comparable polyplex size (150–225 nm) to non-reducible polyplexes (175–260 nm), suggesting that DBM-alkyne and the reducible thioethers did not affect polyplex formation and size. In physiological salt concentrations, relatively good stability is observed as particles remained the same size or only slightly increased in size. Homopolymers of DMAEMA tend to form large complexes and aggregates with DNA (~1 μm); thus, the incorporation of OEGMA was able to stabilize polyplexes in physiological salt concentrations.^{17,19} The uncharged, hydrophilic properties of OEGMA provided steric hindrance

and an extra hydration layer that conferred increased stabilization as reported for other DMAEMA and OEGMA copolymers.^{17–19,35,36} Zeta potential measurements (Fig. S6†) indicate that the net surface charges for both reducible and non-reducible copolymers at N/P = 5 and 10 are all positive (~20–40 mV in water, ~5–20 mV in PBS). A positive charge is necessary for polyplex-mediated gene delivery since the excess positive charge interacts with the negatively charged cell membrane for enhanced uptake and gene delivery.³⁷

Polyplex unpacking in non-reducible and reducible conditions was assessed by incubating YOYO-1-labeled DNA polyplexes with heparin sulfate and glutathione (Fig. S7†). In condensed complexes, the YOYO-1 fluorescence is self-quenching; however, as the polyplex unpacks, the fluorescence is recovered. When comparing the heparin only *versus* heparin and glutathione conditions, the reducible medium MW and




Fig. 3 Average diameter of reducible and non-reducible polymer polyplexes measured by DLS. Polyplexes were formed in water and allowed to form for 10 minutes. Afterwards, polyplexes were diluted with water or 150 mM PBS and measured by DLS. Data is presented as mean \pm SD, $n = 3$.

high MW polyplexes unpackaged more after exposure to a reducing environment. These results suggest that cleavable thioether bonds of the reducible, DBM-linked polymers were able to mediate greater DNA unpackaging in the presence of glutathione.

In vitro transfection and cytotoxicity

To investigate the effect of cleavable linkages on transfection efficiency, polymers were complexed with the luciferase reporter plasmid at N/P = 5 and 10 and exposed to HeLa cells. Branched polyethylenimine (bPEI, 25k) at an N/P = 5 was used as a standard for comparison. Transfection efficiency of both reducible and non-reducible polymers improved with increasing molecular weight as seen with other DMAEMA and OEGMA copolymers and other cationic systems (Fig. 4a).³⁶ The transfection

efficiencies of the polyplexes were comparable with only 5 of the 12 reducible and analogous non-reducible polyplex sets showing statistically significant differences in transfection efficiency ($P < 0.05$), as marked by an (*) in Fig. 4a. The reducible polymers had higher transfection efficiency for two of the statistically significant sets while the non-reducible polymers had higher transfection efficiency for the other three statistically significant sets. This suggests that polymer reducibility did not greatly affect transfection efficiency.

The cytotoxicity of the polymers was assessed by measuring the total protein content in cell lysates after transfection as compared to untreated cells (Fig. 4b). Larger molecular weight copolymers were more cytotoxic than smaller copolymers as is reported for other systems.⁸ Overall, the reducible, DBM-substituted polymers had higher cell viabilities than their non-reducible counterparts in both OptiMEM™ and serum. Seven of the 12 analogous polymer sets showed statistically significant ($P < 0.05$) differences in cytotoxicity, as marked with an (*). The reducible polymers had better viability for six of the statistically significant sets, suggesting that the reducible polyplexes were less cytotoxic than the non-reducible polyplexes. The reducible nature of the DBM-substituted polyplexes allowed the large size of positive charge to more readily disassemble into smaller, less toxic pieces as reported for other reducible systems.^{20,22,25}

IC₅₀ study

While the reducible polyplexes were less toxic than the non-reducible polyplexes, there is a lack of direct measurement of polymer toxicity without DNA. An MTS assay with HeLa cells was conducted to determine half maximal inhibitory concentration (IC₅₀) values of polymers alone without DNA (Table 2). The IC₅₀ values were based on DMAEMA monomer concentration to account for differences in molecular weight, amount of DMAEMA incorporation, and because the cytotoxicity of the




Fig. 4 (a) Luciferase plasmid transfection efficiency and (b) cytotoxicity of reducible DBM-alkyne and non-reducible low, medium, and high MW polyplexes at N/P ratios = 5 and 10. Naked DNA and bPEI (25 kD) controls are included for comparison. Data is presented as mean \pm SD, $n = 4$. Statistically significant ($P < 0.05$) differences are indicated with a (*).

Table 2 IC₅₀ values for the reducible and non-reducible DMAEMA and OEGMA copolymers based on [DMAEMA]

Type of polymer	Low molecular weight	Medium molecular weight	High molecular weight
DBM-substituted p(DMAEMA- <i>s</i> -OEGMA)	119 μM	31.7 μM*	5.97 μM*
Non-reducible p(DMAEMA- <i>s</i> -OEGMA)	96.0 μM	26.2 μM	3.51 μM

*indicates reducible polymers were less toxic than their counterpart and statistically significant ($P < 0.05$).

polymers is heavily based on the cationic charge. The reducible polymers had higher IC₅₀ values than their non-reducible counterparts, consistent with the lower toxicity seen with reducible polyplexes in Fig. 4b. Statistically significant ($P < 0.05$) differences are marked with an (*). The IC₅₀ decreased with increasing molecular weight which is also consistent with the trend that larger molecular weight polymers are less tolerated by cells.⁸

Cleavage of the reducible high and medium MW polymers results in polymers similar in size to the non-reducible medium and low MW polymers, respectively. Therefore,




Fig. 5 (a) Histograms representing the data and (b) average fluorescence as assessed by flow cytometry. Uptake of fluorophore, non-functionalized polyplexes, polyplexes plus free fluorophore, and fluorophore-functionalized polyplexes was monitored in HeLa cells. Data is presented as mean \pm SD, $n = 4$. Statistically significant ($P < 0.05$) differences are indicated with a (*).

similar IC_{50} values might be expected for these pairs of polymers; however, the IC_{50} value of the reducible polymer is lower in each case. The higher cytotoxicity from the reducible polymer compared to the lower molecular non-reducible polymer may be due to the kinetics and location of the dithio-maleimide reduction. The expected location for reduction of DBM-substituted polymers is in the cytoplasm and another 2 hours is needed for complete reduction of thioether bonds once inside the cell cytoplasm.²⁸ In addition, there is a higher concentration of reduced polymer than the non-reducible polymer since the reduction of each DBM-substituted polymer yields two polymers. Nonetheless, the reducible polymers are less toxic than their non-reducible counterparts. Together with the glutathione reduction study (Fig. 2), these results suggest that the DBM-substituted polymers are better tolerated by mammalian cells compared to their non-reducible counterparts due to fragmentation triggered after cellular internalization.

Polyplex uptake by flow cytometry

The reducible, DBM-substituted polymers may be easily modified at the alkyne functional group by using azide-alkyne cycloaddition. Most cationic polymers are functionalized by reaction with their primary amines; however, this can be undesirable in gene transfer applications since amine reactions may interfere with nucleic acid packaging. Therefore, the DBM-alkyne provides a location for site-specific functionalization without affecting polymer charge. As a proof-of-concept, we functionalized the DBM-substituted polymers with azide-modified rhodamine fluorophores (Scheme 1a) and used flow cytometry to monitor cellular uptake of the fluorescently-labeled polyplexes. Fluorophore alone, un-functionalized polyplexes, un-functionalized polyplexes with free fluorophore, and fluorophore-functionalized polyplexes were incubated with cells and polymer uptake was analyzed by flow cytometry (Fig. 5). Statistically significant ($P < 0.05$) differences are marked with an (*). Cells treated with fluorophore-labeled polyplexes exhibited the highest levels of mean fluorescence intensity compared to the fluorophore only, polymer only, and polyplex with free fluorophore groups. Thus, the fluorophore-labeled polymers were able to monitor the uptake of the polyplexes.

In addition to imaging agents, these DBM-linked conjugates can be functionalized with other moieties such as peptides and antibodies. The DBM-alkyne derivative provides a site-specific and quantity-controlled method of conjugation that is less promiscuous than other conjugation methods such as amine chemistry. Another possible application is to use the alkyne handle to immobilize polymers or polyplexes to azide-functionalized surfaces. Polymers or drug carriers can then be easily released from surfaces by a reducing agent such as glutathione.

Conclusion

A panel of reducible and non-reducible DMAEMA and OEGMA copolymers was synthesized by ATRP. The double-headed polymers were reduced and substituted onto a DBM-alkyne

derivative. All polymers condensed plasmid DNA and were stable in water and physiological salt concentrations. The reducibility afforded by DBM did not have a significant effect on transfection efficiency; however, it did confer much reduced cytotoxicity since the polymer can dissociate in the reducing environment of the cell cytoplasm. In addition to lowering cytotoxicity, DBM-alkyne provided a site-specific and quantity-controlled place of attachment. A fluorophore was clicked onto the DBM-linked polymers and these polyplexes were able to monitor cell uptake. The site-specific and quantity-controlled functionalization of DBM may allow for more controlled conjugation of biomolecules such as peptides and antibodies.

Acknowledgements

This work was supported by NIH 2R01 NS064404. JKYT is supported by an NSF Graduate Research Fellowship (2011128558). We would also like to thank David S. Chu for his expertise and guidance and Binhan Pham for his assistance.

Notes and references

- 1 C. E. Thomas, A. Ehrhardt and M. A. Kay, *Nat. Rev. Genet.*, 2003, **4**, 346–358.
- 2 T. Niidome and L. Huang, *Gene Ther.*, 2002, **9**, 1647–1652.
- 3 D. W. Pack, A. S. Hoffman, S. Pun and P. S. Stayton, *Nat. Rev. Drug Discovery*, 2005, **4**, 581–593.
- 4 B. Abdallah, A. Hassan and C. Benoist, *Hum. Gene Ther.*, 1996, **7**, 1947–1954.
- 5 M. Jäger, S. Schubert, S. Ochrimenko, D. Fischer and U. S. Schubert, *Chem. Soc. Rev.*, 2012, **41**, 4755–4767.
- 6 M. S. Al-Dosari and X. Gao, *AAPS J.*, 2009, **11**, 671–681.
- 7 H. Lv, S. Zhang, B. Wang, S. Cui and J. Yan, *J. Controlled Release*, 2006, **114**, 100–109.
- 8 D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein and T. Kissel, *Biomaterials*, 2003, **24**, 1121–1131.
- 9 J. G. Schellinger, J. A. Pahang, R. N. Johnson, D. S. H. Chu, D. L. Sellers, D. O. Maris, A. J. Convertine, P. S. Stayton, P. J. Horner and S. H. Pun, *Biomaterials*, 2013, **34**, 2318–2326.
- 10 D. S. H. Chu, J. G. Schellinger, M. J. Bocek, R. N. Johnson and S. H. Pun, *Biomaterials*, 2013, **34**, 9632–9637.
- 11 K. Wong, G. Sun, X. Zhang, H. Dai, Y. Liu, C. He and K. W. Leong, *Bioconjugate Chem.*, 2006, **17**, 152–158.
- 12 P. Erbacher, S. Zou and T. Bettinger, *Pharm. Res.*, 1998, **15**.
- 13 M. Köping-Höggård, K. M. Vårnum, M. Issa, S. Danielsen, B. E. Christensen, B. T. Stokke and P. Artursson, *Gene Ther.*, 2004, **11**, 1441–1452.
- 14 H. Wei, J. A. Pahang and S. H. Pun, *Biomacromolecules*, 2013, **14**, 275–284.
- 15 D. S. H. Chu, R. N. Johnson and S. H. Pun, *J. Controlled Release*, 2012, **157**, 445–454.
- 16 R. N. Johnson, R. S. Burke, A. J. Convertine, A. S. Hoffman, P. S. Stayton and S. H. Pun, *Biomacromolecules*, 2010, **3007**–3013.

- 17 U. Rungsardthong, M. Deshpande, L. Bailey, M. Vamvakaki, S. P. Armes, M. C. Garnett and S. Stolnik, *J. Controlled Release*, 2001, **73**, 359–380.
- 18 S. Uzgün, O. Akdemir, G. Hasenpusch, C. Maucksch, M. M. Golas, B. Sander, H. Stark, R. Imker, J.-F. Lutz and C. Rudolph, *Biomacromolecules*, 2010, **11**, 39–50.
- 19 M. C. Deshpande, M. C. Davies, M. C. Garnett, P. M. Williams, D. Armitage, L. Bailey, M. Vamvakaki, S. P. Armes and S. Stolnik, *J. Controlled Release*, 2004, **97**, 143–156.
- 20 Y.-Z. You, D. S. Manickam, Q.-H. Zhou and D. Oupický, *J. Controlled Release*, 2007, **122**, 217–225.
- 21 Y. Zhang, M. Zheng, T. Kissel and S. Agarwal, *Biomacromolecules*, 2012, **13**, 313–322.
- 22 M. A. Gosselin, W. Guo and R. J. Lee, *Bioconjugate Chem.*, 2001, **12**, 989–994.
- 23 L. V. Christensen, C.-W. Chang, W. J. Kim, S. W. Kim, Z. Zhong, C. Lin, J. F. J. Engbersen and J. Feijen, *Bioconjugate Chem.*, 2006, **17**, 1233–1240.
- 24 R. S. Burke and S. H. Pun, *Bioconjugate Chem.*, 2010, **21**, 140–150.
- 25 H. Wei, J. G. Schellinger, D. S. H. Chu and S. H. Pun, *J. Am. Chem. Soc.*, 2012, **134**, 16554–16557.
- 26 Q. Peng, Z. Zhong and R. Zhuo, *Bioconjugate Chem.*, 2008, **19**, 499–506.
- 27 M. E. B. Smith, F. F. Schumacher, C. P. Ryan, L. M. Tedaldi, D. Papaioannou, G. Waksman, S. Caddick and J. R. Baker, *J. Am. Chem. Soc.*, 2010, **132**, 1960–1965.
- 28 P. Moody, M. E. B. Smith, C. P. Ryan, V. Chudasama, J. R. Baker, J. Molloy and S. Caddick, *ChemBioChem*, 2012, **13**, 39–41.
- 29 Y. Cui, Y. Yan, Y. Chen and Z. Wang, *Macromol. Chem. Phys.*, 2013, **214**, 470–477.
- 30 M. W. Jones, R. A. Strickland, F. F. Schumacher, S. Caddick, J. R. Baker, M. I. Gibson and D. M. Haddleton, *J. Am. Chem. Soc.*, 2012, **134**, 1847–1852.
- 31 P. van de Wetering, J. Y. Cherng, H. Talsma, D. J. Crommelin and W. E. Hennink, *J. Controlled Release*, 1998, **53**, 145–153.
- 32 M. P. Robin, P. Wilson, A. B. Mabire, J. K. Kiviahio, J. E. Raymond, D. M. Haddleton and R. K. O'Reilly, *J. Am. Chem. Soc.*, 2013, **135**, 2875–2878.
- 33 J. M. Layman, S. M. Ramirez, M. D. Green and T. E. Long, *Biomacromolecules*, 2009, **10**, 1244–1252.
- 34 C. P. Ryan, M. E. B. Smith, F. F. Schumacher, D. Grohmann, D. Papaioannou, G. Waksman, F. Werner, J. R. Baker and S. Caddick, *Chem. Commun.*, 2011, **47**, 5452–5454.
- 35 F. J. Verbaan, C. Oussoren, C. J. Snel, D. J. Crommelin, W. E. Hennink and G. Storm, *J. Gene Med.*, 2004, **6**, 64–75.
- 36 S. Venkataraman, W. L. Ong, Z. Y. Ong, S. C. Joachim Loo, P. L. R. Ee and Y. Y. Yang, *Biomaterials*, 2011, **32**, 2369–2378.
- 37 J. P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M. J. Gait, L. V. Chernomordik and B. Lebleu, *J. Biol. Chem.*, 2003, **278**, 585–590.